

ORIGINAL ARTICLE

OPEN

# KIAA1549:BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas

Aline Paixão Becker, MD, MSc, Cristovam Scapulatempo-Neto, MD, PhD, Adriana C. Carloni, MSc, Alessandra Paulino, BSc, Jamie Sheren, PhD, Dara L. Aisner, MD, PhD, Evelyn Musselwhite, MSc, Carlos Clara, MD, PhD, Hélio R. Machado, MD, PhD, Ricardo S. Oliveira, MD, PhD, Luciano Neder, MD, PhD, Marileila Varella-Garcia, PhD, and Rui M. Reis, PhD

## Abstract

Up to 20% of patients with pilocytic astrocytoma (PA) experience a poor outcome. *BRAF* alterations and *Fibroblast growth factor receptor 1 (FGFR1)* point mutations are key molecular alterations in PA, but their clinical implications are not established. We aimed to determine the frequency and prognostic role of these alterations in a cohort of 69 patients with PAs. We assessed *KIAA1549:BRAF* fusion by fluorescence in situ hybridization and *BRAF* (exon 15) mutations by capillary sequencing. In addition, *FGFR1* expression was analyzed using immunohistochemistry, and this was compared with gene amplification and hotspot mutations (exons 12 and 14) assessed by fluorescence in situ hybridization and capillary sequencing. *KIAA1549:BRAF* fusion was identified in almost 60% of cases. Two tumors harbored mutated *BRAF*. Despite high *FGFR1* expression overall, no cases had *FGFR1* amplifications. Three cases harbored a *FGFR1* p.K656E point mutation. No correlation was observed between *BRAF* and *FGFR1* alterations. The cases were predominantly pediatric (87%), and no statistical differences were observed in molecular alterations–related patient ages. In summary, we confirmed the high frequency of *KIAA1549:BRAF* fusion in PAs and its association with a better outcome. Oncogenic mutations of *FGFR1*, although rare, occurred in a subset of patients with worse outcome. These

molecular alterations may constitute alternative targets for novel clinical approaches, when radical surgical resection is unachievable.

**Key Words:** *BRAF*, Brain tumor, *FGFR1*, Glioma, Molecular diagnosis, Pilocytic astrocytoma, Prognosis.

## INTRODUCTION

Pilocytic astrocytomas (PAs) are the major solid neoplasms in children and teenagers (1, 2). According to data from the Central Brain Tumor Registry of the United States, it is the main neoplasm in the 5- to 14-year-old range in the United States (3). Similarly in Brazil, PAs are the second most common neoplasm in pediatric patients after leukemias (4), accounting for almost 20% of primary brain tumors in children (5). Pilocytic astrocytomas are less frequent in adults in whom they are associated with more aggressive clinical courses (1, 6). According to the World Health Organization (WHO), PAs are grade I tumors because of their well-limited and usually indolent nature (1). The 5-year survival rate is >90% in children (1, 7), and 52% in adults (8). Despite the overall good prognosis of PAs, up to 20% of patients will have a poor outcome, with recurrence, growth of incompletely resected lesions, or dissemination through the cerebrospinal fluid, and ultimately death due to disease (1, 7).

Pilocytic astrocytomas can occur throughout the neuraxis, but the most common location of sporadic tumors is the cerebellum (1). Extracerebellar tumors, particularly those located in the cerebral hemispheres and in the optic pathways, have a known association with neurofibromatosis 1 (NF1), a familial tumor predisposition syndrome with autosomal dominant inheritance (1, 9). Approximately 10% of all PAs are related to NF1 (NF1-PAs), and conversely, PAs are the most frequent brain tumor related to NF1 (49% of cases) (10, 11). When these PAs arise in locations where gross total resection is difficult to achieve, they usually follow a more benign course than sporadic PAs (11).

Molecular studies based on the relationship between PAs and NF1 allowed the discovery of germline and somatic mutations with silencing of the tumor suppressor gene *NF1* in NF1-PAs. These were recently defined as point mutations, splice mutations or nonsense mutations (germline mutations) and loss of heterozygosity and epigenetic changes, such as

From the Molecular Oncology Research Center (APB, ACC, AP, RMR), and Department of Pathology (CSN), Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Cancer Center (JS, DLA), and School of Medicine (EM, MVG), University of Colorado, Aurora, Colorado; Department of Neurosurgery(CC), Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Department of Surgery (RSO), and Department of Pathology and Forensic Medicine (APB, LN), Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP), São Paulo, Brazil; Life and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho (RMR), Braga, Portugal; and ICVS/3B's – PT Government Associate Laboratory(RMR), Braga/Guimarães, Portugal.

Send correspondence and reprint requests to: Rui Manuel Reis, PhD, Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Vilela, 1331. Barretos-SP, Brazil; E-mail: ruireis.hcb@gmail.com

This study was partially supported by CNPq/Universal (475358/2011-2), and FAPESP (2012/19590-0) grants to RMR and to the NIH- P30CA046934 (CCSG Molecular Pathology/Cytogenetics) to MVG and DLA.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

methylation of the gene (somatic mutations) (9). These mutations result in loss of expression of neurofibromin, which is a negative signaling regulator of RAS proteins; this results in an increase of activated RAS levels and further activation of the mitogen-activated protein kinase (MAPK) pathway (12). The constitutive activation of the MAPK pathway increases survival and proliferation of cancer cells in various neoplasms (13, 14).

MAPK is a key signaling pathway in the development of PAs; it is altered in up to 90% of cases (7, 15, 16). The major alterations leading to constitutive activation of MAPK in PAs are gene fusions and point mutations involving the oncogene *BRAF* (7, 17–23). Gene fusions between *KIAA1549* and *BRAF* (*KIAA1549:BRAF* fusion) leading to the overexpression of the fusion protein affects up to 80% of PAs. There are decreasing rates with age, varying from 79% in children younger than 10 years to 7% in patients older than 40 years (16, 20); this is associated with a better prognosis in low-grade gliomas, including PAs (21). Less frequent fusions, such as *SRGAP3-RAF1* (24) and *FAM131B-BRAF* (25, 26), have also been described. Another mechanism of sustained *BRAF* activation in PAs is the point mutation V600E, which results in an amino acid substitution at codon 600 in *BRAF*, from a valine (V) to a glutamic acid (E) in the majority of cases, leading to the activation of the kinase domain of this oncogene (7, 18, 22, 27). Nevertheless, this finding is infrequent in PAs (approximately 6%) and may be detected more frequently in other brain tumor types, such as glioblastomas (22, 28), gangliogliomas, and particularly, pleomorphic xanthoastrocytomas (>60%) (16, 22).

Recent studies have identified upstream alterations in the MAPK pathway, mainly in the tyrosine-kinase receptor *Fibroblast growth factor receptor 1* (*FGFR1*), leading to constitutive activation of the growth cascade in PAs (15, 29). In contrast to the *FGFR1* amplification frequently observed in breast, ovary, and lung cancer (30, 31), gene fusions and duplications are described at low frequencies in brain tumors such as glioblastomas (32) and pediatric diffuse astrocytomas (16), respectively. In PAs, the newly described alterations of *FGFR1* are point mutations in the hotspot tyrosine kinase region, affecting mainly the codons 546 (p.N546K –asparagine-to-lysine substitution) and 656 (p.K656E –lysine-to-glutamate substitution) of the gene in extracerebellar PAs (15).

Despite the great improvement in the knowledge on the molecular oncogenesis of PAs in the last years, the main established prognostic factors for PAs remain in the clinical features, such as patient's age, feasibility of radical resection of lesion (33–35), exposure to radiation therapy (1), and the sporadic or hereditary nature of the tumor (12). The prognostic implications of *BRAF* and *FGFR1* alterations have not been fully explored, and advances in this field might identify potential targets for clinical treatment of PA, particularly for the tumors located in eloquent areas where radical resection is rarely achieved.

In this study, we aimed to determine the frequency of the molecular alterations in *BRAF* and *FGFR1* and to evaluate the prognostic role of these oncogenes in a series of Brazilian patients with PAs.

## MATERIALS AND METHODS

### Patients

Sixty-nine patients from the Barretos Cancer Hospital (HCB) and the Hospital of Clinics of Faculty of Medicine of Ribeirão Preto (HCRP), from 1993 to 2013, were included in this study. The patients were clustered according to sex, age group ( $\leq 19$  years old vs  $\geq 20$  years old), clinical diagnosis of NF1 (confirmed by standardized clinical criteria), and lesion location (cerebellar vs extracerebellar). The outcome of patients was classified as “favorable” (i.e. patients without any events and/or with Karnofsky index  $\geq 80$  at follow-up) and “unfavorable” (i.e. occurrence of some event and/or Karnofsky index  $\leq 70$  at follow-up). We defined “event” as death, growth of a partially resected lesion, or the recurrence of a completely resected lesion confirmed by immediate postsurgical computed tomography (36), detected either clinically and/or through neuroradiologic examinations. The study was approved by both local Ethics Committee (protocols HCB 87362 and HCRP 212.313).

The series included 38 male and 31 female patients (ratio, 1.2:1), with ages ranging from 0.3 to 53.4 years old (median, 9.1 years old). The 5-year and 10-year survival of the series were  $> 95\%$  and  $80\%$ , respectively. Overall, 35 cases (50.7%) had unfavorable outcomes according to our criteria: 8 patients (11.5%) had relapsing or growing residual tumors; 23 patients (33.3%) developed moderate to severe clinical deficits (Karnofsky index, 50–70); and 4 patients (5.8%) died of disease. The deaths occurred after 1.7, 2.6, 6.5, and 10.7 years of the diagnosis, respectively. Two deceased patients had cerebellar lesions with subsequent medullary dissemination of the tumor, 1 patient had a suprasellar lesion, and the other had an insular tumor. Table 1 summarizes clinical data of the patients.

Of the 69 patients included in this study, 5 had relapsed lesions analyzed, and 1 of these had yet a second relapsed lesion analyzed, totaling 75 samples. All cases were reviewed by 2 neuropathologists, according to the 2007 WHO diagnostic criteria (1); negative immunohistochemical reaction to mutated *IDH1* was found in all cases (37, 38).

We constructed 2 blocks of tissue microarray (TMA) from the formalin-fixed, paraffin-embedded (FFPE) samples, using the Beecher Instruments TMA platform, with tissue cores at 1 mm diameter for the HCB cases and 1.5 mm for the HCRP cases. Because of the histologic heterogeneity of the PAs, we obtained up to 8 cores of each case (average, 3.6 cores/case), representing the different histologic patterns of the tumors. In 9 cases, adjacent nonneoplastic cerebellar tissue was available and included in the TMA.

### Immunohistochemistry

Automated immunohistochemistry using Ventana BenchMark Ultra equipment (Ventana-Roche, Tucson, AZ) was performed in the TMA slides with 4- $\mu\text{m}$ -thick tissue sections, according to the manufacturer's protocols. First, the sections were deparaffinized and dehydrated, then the antigen retrieval process was done with a mixed citrate/EDTA buffer (pH 6.0, at 125 °C for 4 minutes and 95 °C for 25 minutes in pressure cooker). The monoclonal antibody used was anti-FGFR1 (Cell

Signaling, Danvers, MA, clone D8E4, dilution 1:50). As external controls for the immunohistochemical reaction, we used prostate epithelium and liver; internal control was the endothelial cytoplasmic reaction.

The cytoplasmic expression of FGFR1 was evaluated in a double-blind fashion following semiquantitative criteria based on the intensity (0 = negative, 1 = weak, 2 = moderate, 3 = strong) and extension of the reaction (0, 0% of positive cells; 1, <25% of positive cells; 2, 25%–50% of positive cells; and 3, >50% of positive cells) (39). With the sum of these analyses, we achieved scores ranging from 0 to 6. Samples with scores 0 to 2 were considered negative; those with scores 3 to 6 were considered positive (39). Tissues sections were also evaluated for nuclear expression;  $\geq 25\%$  nuclear staining was considered positive, and cases with <25% of nuclear staining were considered negative. In the cases with more than 1 tissue core, we calculated the average score.

### KIAA1549-BRAF and FGFR1 Fluorescence In Situ Hybridization Assay

For analysis of KIAA1549-BRAF fusion, fluorescence in situ hybridization (FISH) probes were created from BAC clones containing human DNA from regions homologous to the KIAA1549 and BRAF genes on chromosome 7, as identified through the Ensembl Genome Browser (GRCh37). The BRAF DNA was validated by polymerase chain reaction (PCR) using the following sequences as primers: 5'-CAGA GTTTGTCAGATGGTCCCTTT-3' (forward) and 5'-ACCATA TAATAGAAGCGCCTCCCA-3' (reverse). For the KIAA1549 DNA, the validation sequences were 3'-AGGTATTGTTGGA ACATTGAAGGCT-3' (forward) and 5'-CAGTCAAATGCTC GCAATGAATGAA-3' (reverse). DNA inserts were extracted from clone mini-cultures, purified and subjected to whole genome amplification using the REPLI-g Midi Kit from Qiagen (Cat# 150045, Qiagen, Düsseldorf, Germany).

An aliquot of 1  $\mu\text{g}$  of each purified BRAF and KIAA1549 DNA were labeled, respectively, with SpectrumRed and SpectrumGreen conjugated dUTPs using the Vysis Nick Translation Kit (Cat# 32–801300, Abbott Molecular, Des Plaines, IL), as previously reported (40). Labeled DNA was coprecipitated with herring sperm DNA as carrier (1:50) and human Cot-1 DNA (1:10) for blocking of repetitive sequences then diluted 1:10 in t-DenHyb hybridization buffer (Insitus Biotechnologies, Albuquerque, NM). The labeled FISH probe mix was validated for chromosome mapping and quality of hybridization in interphase and metaphase cells prior to this study.

The FFPE slides were deparaffinized and dehydrated according to previously established protocols (41). The probe was applied to the selected areas, and hybridization was allowed to occur at 37 °C for 40 to 67 hours and, finally, the chromatin was counterstained with DAPI/anti-fade (0.3  $\mu\text{g}/\text{mL}$  in Vectashield mounting medium, Vector Laboratories, Burlingame, CA).

Analysis was performed on an epifluorescence microscope using single interference filter sets for green (fluorescein isothiocyanate), red (Texas red), and blue (DAPI), as well as dual (red/green) and triple (blue, red, and green) band pass filters. For each interference filter, monochromatic images were acquired and merged using CytoVision (Leica Microsystems Inc., Wetzlar, Germany). A minimum of 50 tumor nuclei was evaluated.

The specimen was considered positive for the KIAA1549-BRAF fusion when there were doublets of red and green signals very close or partially overlapping observed, as opposed to signals separated by >2 signal diameters, which characterize alleles with native status.

### FGFR1 Amplification

The FGFR1/CEP8 enumeration assay measured 2 genomic targets using 2 commercial FISH probes provided as Analyte Specific Reagents (ASR) by Abbott Molecular (Ref. 08 N21-020 and Ref. 06 J37-018, respectively): Vysis LSI FGFR1 SpectrumRed FISH probe, which contains the entire FGFR1 gene, labeled with SpectrumRed fluorophore, and the CEP 8 (D8Z2) FISH probe, labeled with SpectrumGreen fluorophore.

The FFPE slides were processed and evaluated as previously described for the KIAA1549-BRAF fusion. The determination of low and high level of FGFR1 gene amplification followed the criteria proposed by Schultheis et al (42) based on the ratio FGFR1/CEP 8  $\geq 2.0$ , or the average number of FGFR1 signals per nucleus  $\geq 6$  copies.

### BRF and FGFR1 Point Mutation Analyses

We first obtained serial 10- $\mu\text{m}$ -unstained sections of FFPE blocks. One adjacent hematoxylin and eosin-stained section was used for identification and selection of tumor area by the pathologist. DNA was isolated from 1 or 2 unstained section from each specimen, depending on the size of the tissue fragment, as previously described (43). Briefly, tissues were deparaffinized and dehydrated. Selected areas of tumor were macrodissected using a sterile needle (18G  $\times$  1½) (Becton Dickinson, Curitiba, Brazil), and carefully collected into a microtube. DNA was isolated using QIAamp DNA Micro Kit (Qiagen, Hilden, Germany), following the manufacturer's instructions, followed by evaluation of DNA quantity and quality by Nanodrop 2000 (Thermo Scientific, Wilmington, DE). DNA samples were then diluted to a final concentration of 50 ng/ $\mu\text{L}$  and stored at -20 °C for further molecular analysis.

The whole exons of BRAF (exon 15; codon 600) and FGFR1 (exons 12 and 14; codons 546 and 656) were analyzed by PCR, followed by direct sequencing, with emphasis in the hotspot loci, as previously described (15, 28). Briefly, the PCR reaction was performed in a final volume of 15  $\mu\text{L}$ , under the following conditions: 1  $\times$  PCR buffer (Invitrogen, Carlsbad, CA); 2 mmol/L MgCl<sub>2</sub> (Invitrogen); 10 mmol/L dNTPs (Invitrogen); 0.3 mmol/L of both sense and antisense primers (Sigma Aldrich, St. Louis, MO); 1 unit of Platinum Taq DNA polymerase (Invitrogen); and 50 ng of DNA. The BRAF primers used were TCATAATGCTTGCTCTGATAG GA (sense) and GGCCAAAATTTAATCAGTGA (antisense) (28), for FGFR1 exon 12 TCAAGTCCCAGGGAAAAGCAG (sense) and AGGCCTTGGGACTGATACCC (antisense), and for FGFR1 exon 14 GACAAGTCGGCTAGTTGCAT (sense) and CCCACTCCTTGCTTCTCAGAT (antisense). The PCR was performed in Veriti 96-Well Thermal Cycler (Applied Biosystems, Austin, TX). The PCR products were evaluated by agarose gel electrophoresis prior to capillary sequencing.



TABLE 1. Clinicoepidemiologic Data of the PA Series

ID	Origin	Sex	Age (years)	Location	NF1	Extension of Resection	Event	Status	Follow-Up (months)	
1	P01	HCB	M	4.8	C		Total	Recurrence	AWD	27
2	P02	HCB	M	4.2	C		Total	No	AND	27.5
3	P03	HCB	M	8.4	C		Total	No	AND	36.2
**4	P04	HCB	M	8	C		Partial	Growth	AWD	34.1
*5	P05	HCB	F	15.8	C		Partial	Growth	AND	24.4
6	P06	HCB	M	20.8	C		Partial	No	AWD	16.8
7	P07	HCB	F	35.4	SC		Partial	No	AWD	22.9
8	P08	HCB	M	4.8	C		Partial	Growth	AWD	29.3
9	P10	HCB	M	10.5	C		Total	No	AND	43
10	P12	HCB	M	5.2	C		Total	No	AND	36.5
11	P13	HCB	M	5.1	CH		Partial	No	AWD	53.5
12	P16	HCB	M	53.4	C		Partial	Growth	AWD	34.1
13	P17	HCB	F	19.2	C		Total	No	AND	60.3
14	P18	HCB	F	17	CH		Total	No	AND	65.3
15	P20	HCB	M	9.2	BS		Partial	No	AWD	63.3
16	P21	HCB	M	3.5	C		Total	No	AND	66.6
17	P23	HCB	M	16.4	CH	Yes	Total	No	AND	58.2
18	P24	HCB	M	21.9	CH		Partial	No	AWD	12.9
19	P25	HCB	F	2.1	C		Partial	No	AWD	7.1
20	P26	HCB	M	10.2	C		Total	No	AND	39.2
21	P28	HCB	F	7.5	C		Total	No	AND	86.3
22	P29	HCB	F	5.2	C		Total	No	AND	8.8
23	P30	HCB	M	15.3	C		Partial	Growth	AWD	8
24	P31	HCRP	F	11.3	C		Total	No	AND	133.2
25	P32	HCRP	F	18.1	C		Total	Recurrence	D	20.6
26	P33	HCRP	F	13.8	C		Partial	No	AWD	196.8
27	P34	HCRP	M	5.2	SC		Partial	Growth	AWD	194.7
28	P35	HCRP	M	12.7	C		Total	No	AND	179.1
29	P36	HCRP	F	3.8	C		Total	Recurrence	AND	168.6
30	P37	HCRP	M	11.1	SS		Partial	No	AWD	170.6
31	P38	HCRP	F	9	SC		Partial	Growth	AWD	155
32	P39	HCRP	M	12.8	CH		Partial	Growth	AWD	144.5
33	P40	HCRP	F	3.6	C		Total	No	AND	66.1
*34	P41	HCRP	M	9.6	C		Partial	Growth	D	128.8
35	P42	HCRP	M	5.9	C		Total	No	AND	51.7
36	P43	HCRP	M	3.6	C		Total	No	AND	116.5
37	P44	HCRP	F	2	C		Total	No	AND	115.7
38	P45	HCRP	M	7.1	C		Total	No	AND	112.8
39	P46	HCRP	F	9.9	BS		Partial	No	AWD	91.6
40	P47	HCRP	M	17.4	CH		Total	No	AND	63.7
41	P48	HCRP	F	2.2	C		Total	No	AND	83.2
42	P49	HCRP	F	5.8	BS		Partial	No	AWD	83.4
*43	P50	HCRP	F	5.3	C		Partial	Growth	AND	75.1
44	P51	HCRP	M	27.7	C		Total	No	AND	59.1
45	P52	HCRP	F	16.2	SS		Partial	Growth	D	79.2
46	P53	HCRP	F	11.7	C		Partial	No	AWD	68.6
47	P54	HCRP	M	4.5	OP		Partial	Growth	AWD	19.1
48	P55	HCRP	F	0.3	CH		Partial	Growth	D	31.5
49	P56	HCRP	F	4.1	SS		Partial	No	AWD	66.3
50	P57	HCRP	F	5.7	C		Total	Recurrence	AWD	58.3
51	P58	HCRP	M	3.1	SS		Partial	Growth	AWD	54.1
52	P59	HCRP	M	14.7	CH	Yes	Total	No	AWD	58.7
53	P60	HCRP	M	21.9	OP		Partial	No	AWD	18.9
54	P61	HCRP	M	32.2	CH		Total	No	AND	10.2
55	P62	HCRP	F	14.4	C		Total	No	AND	45.1

(Continued on next page)

**TABLE 1. (Continued)**

56	P63	HCRP	F	16.7	CH		Partial	No	AWD	47
57	P64	HCRP	M	24.8	CH		Partial	No	AWD	50.9
58	P65	HCRP	F	9.1	SC		Total	No	AND	46.1
59	P66	HCRP	F	15.3	CH	Yes	Total	No	AWD	46.9
60	P67	HCRP	M	7.2	BS		Partial	No	AWD	49
61	P68	HCRP	M	28.2	SC		Partial	No	AWD	44.8
62	P69	HCRP	M	4.1	SS		Partial	No	AWD	34.7
63	P70	HCRP	F	4.9	SS		Partial	Growth	AWD	31
64	P71	HCRP	M	5.7	C		Partial	Growth	AWD	22.8
65	P72	HCRP	M	17.4	CH		Total	Recurrence	AWD	18.4
66	P73	HCRP	F	6.9	OP	Yes	Partial	No	AWD	15.5
67	P75	HCRP	F	11	CH	Yes	Partial	No	AWD	7.5
68	P76	HCRP	F	8.5	OP		Partial	No	AWD	7.6
*69	P77	HCRP	M	12.5	C		Partial	Growth	AWD	8.4

AND, Alive, no evidence of disease; AWD, alive, with disease; BS, brainstem; C, cerebellum; CH, cerebral hemispheres; D, death; F, female; M, male; SC, spinal cord; SS, suprasellar; OP, optic pathway. \*Patients with 2 samples in the TMA. \*\*Patients with 3 samples in the TMA.

The PCR products of each analyzed exon were firstly purified with EXOSAP-IT (GE Technology, Cleveland, OH), then, PCR products were submitted to a sequencing reaction using 1 μL of BigDye (Applied Biosystems), 1.5 μL of sequencing buffer (Applied Biosystems) and 3.2 μmol/L of primer. The sequencing reaction was followed by post-sequencing purification with EDTA, alcohol and sodium citrate. The purified products were eluted in HiDi (formamide) and incubated at 90 °C for 5 minutes and at 4 °C for at least 5 minutes. Direct sequencing was carried out on a Genetic Analyzer ABI PRISM® 3500 (Applied Biosystems). The analysis of each sample was done by comparison of electropherogram with Ensembl GeneBank sequence (*BRAF*: ENSG00000157764 and *FGFR1*: ENSG0000007782).

All cases with mutations were confirmed twice with a new PCR and direct sequencing starting from extracted DNA. In addition, for quality controls, a new DNA isolation and further mutation analyses were performed in 10% of cases.

### Statistical Analysis

Statistical analyses were performed with SPSS version 20 for Windows™ (IBM, Chicago, IL) with statistically significant values of  $p < 0.05$ . Differences in molecular alterations of *BRAF* and *FGFR1* between groups were verified by the Fisher exact and the Pearson chi-square tests. Overall survival (OS) and event-free survival (EFS) curves were determined by the Kaplan-Meier method.

## RESULTS

### Molecular Characterization of *BRAF*


The FISH assay for *KIAA1549:BRAF* fusion detection was successful in 64 (92.8%) of 69 primary lesions and in 4 of 5 relapsing lesions, which maintained the expression pattern of their primary counterparts (Fig. 1A, B). Thirty-seven primary lesions (57.8 %) displayed *KIAA1549:BRAF* fusion, with strong positive association with a cerebellar location ( $p < 0.001$ ), and negative association with clinical diagnosis of NF1 ( $p = 0.011$ )

(Table 2). There was a tendency for this alteration to be detected in the younger group, with 55.0% and 44.4% of patients positive for *KIAA1549:BRAF* fusion in the pediatric and adult group, respectively (Table 2). Nevertheless, this difference was not statistically significant. In addition, there were no differences between groups for sex or outcome (Table 2).

Because of compromised DNA quality in some specimens, we were able to obtain conclusive results of *BRAF* point mutations in 48 (69.6%) of 69 primary lesions and in 5 of 5 recurrences. Two cases (4.2%) showed *BRAF* point mutations (Fig. 1C, D). One recurrent suprasellar (hypothalamic) tumor of an 11-year-old male patient (P37, Table 1) had the p.V600E mutation, but the patient had only 1 sample available for molecular analysis, and this tumor was also positive for the *KIAA1549:BRAF* fusion in the FISH assay. In addition, a point mutation p.V600K, with a valine-to-lysine substitution at the codon 600 (Fig. 1D), was detected in a cerebellar PA of an 11-year-old female patient (P31, Table 1), who remains alive without evidence of disease after a long follow-up (11 years). None of these patients with tumors harboring mutated *BRAF* had the clinical diagnosis of NF1. Despite the small number of *BRAF*-mutated cases, we performed statistical analysis but did not identify significant associations between *BRAF* status and patients clinical features (Table 2).

### Molecular Characterization of *FGFR1*

The immunohistochemical expression of *FGFR1* was tested in 74 of 75 samples. Nonneoplastic cerebellum showed cytoplasmic staining only in Purkinje cells and was absent or faintly expressed in the nonneoplastic astrocytes (Fig. 2A, B). In tumor areas, cytoplasmic staining was detected in 51 (73.9%) of 69 primary tumors, regardless of the histologic pattern of the PA (Fig. 2C, D) and no nuclear staining was observed. Forty-nine cases (71%) had scores  $\geq 3$ , and 19 cases (27.5%) were completely negative. No association was found between *FGFR1* immunohistochemical staining with the presence of the *KIAA1549:BRAF* fusion ( $p = 0.272$ ), or with *BRAF* point mutations ( $p = 0.456$ ) (data not shown). No significant




**FIGURE 1.** Molecular alterations in *BRAF*. **(A, B)** FISH assay for detection of *KIAA1549:BRAF* fusion showing a positive **(A)** and a negative **(B)** case (white arrows). **(C, D)** Point mutations detected by Sanger sequencing for V600E **(C)** and V600K **(D)**.

**TABLE 2.** Clinical Features of Patients and Their Association with *BRAF* Changes

	(Total No. in the Series)	<i>KIAA1549:BRAF</i> Fusion		p	<i>BRAF</i> Point Mutation		p
		Positive	Negative		Wild Type	Mutated	
Sex	Female (31)	18	11	0.530	25	1	1.0
	Male (38)	19	16		21	1	
Age	≤19 years (60)	33	22	0.381	40	2	1.0
	≥20 years (09)	4	5		6	0	
NF1	Yes (05)	0	5	0.011	5	0	1.0
	No (64)	37	22		41	2	
Tumor location	Cerebellar (36)	27	6	<0.0001	27	1	1.0
	Extracerebellar (33)	10	21		19	1	
Outcome	Favorable (34)	22	16	0.987	26	1	1.0
	Unfavorable (35)	15	11		20	1	





**FIGURE 2.** Immunohistochemical expression of FGFR1. **(A)** In normal cerebellum, expression is limited to Purkinje cells. **(B)** Neoplastic cells show overexpression when compared with nonneoplastic astrocytes (bottom). **(C)** Oligodendroglial pattern of PA, showing moderate FGFR1 expression. **(D)** Piloid pattern of PA with similar FGFR1 expression.

associations were seen between expression and clinical features of the patients (Table 3).

Sanger sequencing for *FGFR1* was performed in 45 (65.2%) of 69 primary lesions and in 5 of 5 relapsed lesions. Among primary lesions, 3 (6.7%) of 45 carried the p.K656E point mutation (Fig. 3A): an 18-year-old female (P32), a 3-year-old male (P21), and a 2-year-old female (P44) patient. All of these patients had cerebellar lesions (Tables 1 and 3). The older patient had recurrence of a completely resected lesion 8 months after the first surgery with cerebrospinal fluid dissemination despite adjuvant chemotherapy, and she died 21 months after the original surgery. On the other hand, the youngest patient had the best outcome of the subgroup (i.e. no evidence of disease after 9 years of follow-up), had a tumor that was also positive for the *KIAA1549:BRAF* fusion by FISH assay. No association was observed between *FGFR1* mutation and the patients' clinicopathologic characteristics

(Table 3) or FGFR protein expression ( $p = 0.086$ , data not shown), as 2 of the 3 mutated cases had positive scores and 1 had a negative immunohistochemical score.

The FISH assay for *FGFR1* was successful in 61 of the 69 primary lesions and in all 5 of the relapsed lesions; none showed gene amplification (Fig. 3B), but 7 (10.6 %) of 66 cases had a low level of copy number gain (Fig. 3C), which was not statistically related to any clinical feature (Table 3). The patient who had a poor outcome (P32) had a concomitant *FGFR1* point mutation and low copy number gain of *FGFR1* by FISH. The association between low copy number gain of *FGFR1* and the immunohistochemical expression of FGFR1 was not significant ( $p = 0.091$ , data not shown).


### Prognostic Role of *BRAF* and *FGFR1*

The Kaplan-Meier survival curves showed that the presence of *KIAA1549:BRAF* fusion was significantly associated

**TABLE 3.** Clinical Features of Patients and Their Association with *FGFR1* Changes

		FGFR1 Expression		p	FGFR1 lcn <sup>a</sup>		p	FGFR1 Point Mutation		p
		Positive	Negative		Positive	Negative		Wild Type	Mutated	
Sex	Female	22	9	0.994	3	24	1.0	23	2	1.0
	Male	27	11		4	30		19	1	
Age	≤19 years	43	17	0.758	6	47	0.922	37	3	1.0
	≥20 years	6	3		1	7		5	0	
NF1	Yes	4	1	1.0	0	5	1.0	5	0	1.0
	No	45	19		7	49		37	3	
Tumor location	Cerebellar	27	9	0.446	5	26	0.425	24	3	0.264
	Extracerebellar	22	11		2	28		18	0	
Outcome	Favorable	22	12	0.255	2	33	0.125	25	2	1.0
	Unfavorable	27	8		5	21		17	1	

Lcn<sup>a</sup>, low copy number gain.



**FIGURE 3.** Molecular alterations of *FGFR1*. **(A)** Electropherogram showing the point mutation K656E. **(B, C)** FISH assay displaying a normal pattern **(B)**, and a case with low-copy number gain of the *FGFR1* signal **(C)**. The amount of *FGFR1* signals (green) did not reach the cutoff value needed for the diagnosis of gene amplification.



with patients' longer OS ( $p = 0.009$ ) and EFS ( $p = 0.018$ ) (Fig. 4A, B). *BRAF* point mutations were not associated with differences in the OS ( $p = 0.527$ ), nor in the EFS ( $p = 0.317$ ).

FGFR1 immunohistochemical expression and low copy number gain were not correlated with OS ( $p = 0.103$ ) or EFS ( $p = 0.923$ ). On the other hand, patients with the *FGFR1* p.K656E point mutation had significantly shorter OS ( $p = 0.047$ ) and EFS ( $p = 0.025$ ) when compared with patients with wild-type tumors (Fig. 4C, D).

Finally, we assessed the combined impact of *BRAF* and *FGFR1* alterations in patients OS and EFS. We found that patients with tumors positive for *KIAA1549:BRAF* fusion showed longer survival regardless of *FGFR1* status and FGFR1 immunohistochemical expression (Fig. 5A, B). Distinctively, among the tumors negative for *KIAA1549:BRAF* fusion, the ones with the *FGFR1* p.K656E point mutation had significantly worse prognosis ( $p = 0.002$ ), whereas the overexpression of FGFR1 was related to a better prognosis ( $p = 0.03$ ) (Fig. 5A, B).

## DISCUSSION

We have shown in a series of 69 WHO grade I PAs that *KIAA1549:BRAF* fusions are present in most of the cases and that they are associated with better prognosis. In addition, we found that *FGFR1* is altered by oncogenic mutations in a small subset (~7%) of cases that were associated with an adverse outcome.

Despite the emergent interest in children's brain tumors, many studies have clustered PAs, diffuse astrocytomas (WHO grade II), and other neoplasms in a set of "low-grade gliomas" (16, 21, 23, 44–47). This has probably occurred because of the rarity of these brain tumors compared with the much more frequent adult tumors, such as glioblastoma (3). In addition, the studies tend to isolate adults from children (6, 8). As far as we are aware, this is the first study with a cohort composed exclusively of PAs, excluding the pilomyxoid astrocytoma variant of PA (WHO grade II), and comparing different age groups.





FIGURE 4. (A–D) Kaplan-Meier curves showing the impact of *KIAA1549:BRAF* (*K:B*) fusion (A, B) and *FGFR1* p.K656E point mutation (C, D) in the overall survival and event-free survival of the patients.



**FIGURE 5.** Kaplan-Meier curves comparing the simultaneous impact of *KIAA1549:BRAF* (*K:B*) fusion and *FGFR1* alterations on the overall survival of patients. **(A)** Impact of *FGFR1* p.K656E point mutation. **(B)** Impact of *FGFR1* expression assessed by immunohistochemistry (positive score  $\geq 3$ ; negative score  $\leq 2$ ).

Herein, we were able to evaluate gene fusions and point mutations in 67 of 69 cases and observed that nearly 60% of them had alterations in *BRAF* and/or *FGFR1*, which are triggers of the MAPK pathway, the dominant oncogenic pathway of PAs (15, 19). The high incidence of *KIAA1549:BRAF* fusion and its predominance in cerebellar lesions are in line with previous studies (7, 15, 16, 24, 26), confirming it as the most frequent molecular change of PAs (7). In addition, 2 of 5 tumors that harbored *BRAF* or *FGFR1* mutations had a coexisting *KIAA1549:BRAF* gene fusion. The occurrence of a concomitant *KIAA1549:BRAF* fusion and other changes in the same pathway is a rare occurrence, but it has been previously reported (7, 21, 26). Finally, the negative relationship between *KIAA1549:BRAF* fusions and clinical diagnosis of NF1 (thus with alterations in the *NF1* gene) has been previously reported (7). Further studies on *NF1* are necessary for a better understanding of this relationship.

The incidence of *BRAF* point mutations in our study (4.2%) is also similar to published data (22). The presence of this alteration did not show a clinical impact on prognosis, thereby confirming the previous findings of Bannykh et al, who showed that the *BRAF* V600E mutation did not imply higher aggressiveness to PAs (48). The usual p.V600E point mutation was detected only in an 11-year-old male patient who had an unstable hypothalamic lesion, which reinforces the occurrence of this mutation in extracerebellar lesions (7). Moreover, that patient also harbored the *KIAA1549:BRAF* fusion. We also observed 1 unusual *BRAF* point mutation in codon 600 of a cerebellar PA. The point mutation V600K was found in an 11-year-old female patient who had an excellent outcome after long follow-up (11.1 years). This mutation was previously described in 5% to 15% of melanomas and was related to metastatic disease and worse outcome (49–51); however, it has also been associated with a response to first-generation *BRAF* inhibitors (PLX4032, vemurafenib) (51). Patients with PAs have experienced adverse results after

treatment with vemurafenib (52), as opposed to the good response observed in patients with high-grade tumors (53, 54), probably because of the overall low frequency of p.V600E. Nevertheless, the subset of patients with *KIAA1549:BRAF* positive tumors could potentially benefit from treatment with the second-generation *BRAF* inhibitors such as PLX-PB3, which specifically target the fusion protein (52).

Most tumors in our series showed strong immunohistochemical *FGFR1* expression. These findings are in line with a previous study in gliomas, in which *FGFR1* overexpression was detected, although the underlying molecular mechanism was not explained at the time (55). Our FISH assays largely eliminated amplification as the underlying mechanism in the PAs, contrary to what is seen in a subset of breast and lung cancers (30, 31). *FGFR1* low copy number gain was rare and showed a nonstatistically significant trend toward immunohistochemical overexpression ( $p = 0.094$ , data not shown). The mutated form of *FGFR1* was also not associated with protein overexpression ( $p = 1.0$ ).

With respect to the *FGFR1* mutation, we observed p.K656E point mutations at the tyrosine kinase domain in 6.7% of the PAs in this series, all of which were located in the cerebellum. The oncogenic *FGFR1* mutations, p.K656E and p.N456K, were recently described by Jones et al (15) as recurrent events in extracerebellar PAs. Those mutations were further described in rosette-forming glioneuronal tumor of the fourth ventricle, but 1 of the patients in that series had an earlier extracerebellar (diencephalic) PA with pilomyxoid features, which also harbored the p.K656E mutation (29).

*FGFR1* is currently an attractive therapeutic target, and the immunohistochemical assessment of *FGFR1* may represent a good indicator of the management of PAs. Recent studies have related the efficacy of novel specific *FGFR1* inhibitors, such as ponatinib (AP 24534), in cases of lung cancer with *FGFR1* overexpression that were assessed by immunoblotting and mRNA quantification (56). Besides this drug, other

FGFR1 inhibitors, such as lucitanib (57) and CH5183284/Debio 1347 (58), may constitute future alternatives for the treatment of inoperable PAs. Nevertheless, further preclinical and clinical studies are needed to determine whether FGFR1 expression and hotspot mutations will modulate and predict patient response to these FGFR1-specific tyrosine inhibitors.

Concomitant *KIAA1549:BRAF* fusion and *FGFR1* mutations were not referred events in the study of Jones et al (15), but this was detected in 1 of the patients of our series. We further evaluated the impact of both the aforementioned alterations in the prognosis of the patients. The *KIAA1549:BRAF* fusion had a positive impact on patients' OS and EFS and was confirmed as a prognostic factor, corroborating the tendency to better outcome of PAs, similar to what happens in the complex group of low-grade gliomas described by Hawkins et al (21).

On the other hand, *FGFR1* mutations were significantly related to PA patients' shorter OS and EFS when compared with the wild-type group; however, the significance of this finding needs to be confirmed in larger series. To our knowledge, this the first study to indicate the prognostic role of *FGFR1* mutation in PAs and their occurrence in cerebellar lesions.

In conclusion, we confirmed the pivotal role of *KIAA1549:BRAF* fusion and, to a lesser extent, of *FGFR1* in MAPK activation in PAs. More exactly, we showed the usefulness of evaluating the *KIAA1549:BRAF* fusion as a prognostic biomarker, while *FGFR1* mutation may be a relevant prognostic marker in PAs. With further investigation, the molecular changes of *BRAF* and *FGFR1* may constitute potential therapeutic targets for inoperable or recurrent PAs.

### ACKNOWLEDGMENT

The authors thank Nathalia Campanella for the help in picture editing.

### REFERENCES

- Scheithauer BW, Hawkins C, Tihan T, et al. Pilocytic astrocytoma. In: David N, Louis MD, Hiroko Ohgaki PD, Otmar D, Wiestler MD, Webster K, Cavenee PD, editors. *WHO Classification of Tumours of the Central Nervous System. World Health Organization Classification of Tumours*. Lyon, France: IARC Press, 2007:13–21
- Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. *CA Cancer J Clin* 2014;64:83–103
- Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. *Neuro Oncol* 2012;14(Suppl 5):v1–49
- Camargo Bd, Felipe CFP, Noronha CP, et al. *Câncer na criança e no adolescente no Brasil dados dos registros de base populacional e de mortalidade*. Rio de Janeiro: Instituto Nacional do Câncer, 2008
- Rosemberg S, Fujiwara D. Epidemiology of pediatric tumors of the nervous system according to the WHO 2000 classification: a report of 1,195 cases from a single institution. *Child Nerv Sys* 2005;21:940–4
- Theeler BJ, Ellezam B, Sadighi ZS, et al. Adult pilocytic astrocytomas: clinical features and molecular analysis. *Neuro Oncol* 2014 2014;16:841–7. doi: 10.1093/neuonc/not246
- Jones DT, Gronych J, Lichter P, et al. MAPK pathway activation in pilocytic astrocytoma. *Cell Molec Life Sci* 2012;69:1799–811
- Johnson DR, Brown PD, Galanis E, et al. Pilocytic astrocytoma survival in adults: analysis of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. *J Neuro-oncol* 2012;108:187–93
- Gutmann DH, McLellan MD, Hussain I, et al. Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. *Genome Res* 2013;23:431–9
- Rodriguez FJ, Perry A, Gutmann DH, et al. Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. *J Neuropathol Exp Neurol* 2008;67:240–9
- Listernick R, Charrow J, Gutmann DH. Intracranial gliomas in neurofibromatosis type 1. *Am J Med Gen* 1999;89:38–44
- Tada K, Kochi M, Saya H, et al. Preliminary observations on genetic alterations in pilocytic astrocytomas associated with neurofibromatosis 1. *Neuro Oncol* 2003;5:228–34
- Dhanasekaran DN, Johnson GL. MAPKs: function, regulation, role in cancer and therapeutic targeting. *Oncogene* 2007;26:3097–9
- Murphy T, Hori S, Sewell J, et al. Expression and functional role of negative signalling regulators in tumour development and progression. *Int J Cancer* 2010;127:2491–9
- Jones DT, Hutter B, Jager N, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. *Nature Gen* 2013;45:927–32
- Zhang J, Wu G, Miller CP, et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. *Nature Gen* 2013;45:602–12
- Bar EE, Lin A, Tihan T, et al. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. *J Neuropathol Exp Neurol* 2008;67:878–87
- Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. *Acta Neuropathol* 2011;122:11–9
- Forshew T, Tatevossian RG, Lawson AR, et al. Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. *J Pathol* 2009;218:172–81
- Hasselblatt M, Riesmeier B, Lechtape B, et al. BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults. *Neuropathol Appl Neurobiol* 2011;37:803–6
- Hawkins C, Walker E, Mohamed N, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. *Clin Cancer Res* 2011;17:4790–8
- Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. *Acta Neuropathol* 2011;121:397–405
- Tian Y, Rich BE, Vena N, et al. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. *J Molec Diag* 2011;13:669–77
- Jones DT, Kocialkowski S, Liu L, et al. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. *Oncogene* 2009;28:2119–23
- Roth JJ, Santi M, Pollock AN, et al. Chromosome band 7q34 deletions resulting in KIAA1549-BRAF and FAM131B-BRAF fusions in pediatric low-grade gliomas. *Brain Pathol* 2015;25:182–92
- Cin H, Meyer C, Herr R, et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. *Acta Neuropathol* 2011;121:763–74
- Chen YH, Gutmann DH. The molecular and cell biology of pediatric low-grade gliomas. *Oncogene* 2014;33:2019–26
- Basto D, Trovisco V, Lopes JM, et al. Mutation analysis of B-RAF gene in human gliomas. *Acta Neuropathol* 2005;109:207–10
- Gessi M, Moneim YA, Hammes J, et al. FGFR1 mutations in rosette-forming glioneuronal tumors of the fourth ventricle. *J Neuropathol Exp Neurol* 2014;73:580–4
- Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. *PLoS One* 2011;6:e20351
- Theillet C, Adelaide J, Louason G, et al. FGFR1 and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. *Genes Chromosome Cancer* 1993;7:219–26
- Singh D, Chan JM, Zoppoli P, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. *Science* 2012;337:1231–5
- Colin C, Padovani L, Chappe C, et al. Outcome analysis of childhood pilocytic astrocytomas: a retrospective study of 148 cases at a single institution. *Neuropathol Appl Neurobiol* 2013;39:693–705
- Fernandez C, Figarella-Branger D, Girard N, et al. Pilocytic astrocytomas in children: prognostic factors—a retrospective study of 80 cases. *Neurosurgery* 2003;53:544–53; discussion 54–5



35. Paixao Becker A, de Oliveira RS, Saggiaro FP, et al. In pursuit of prognostic factors in children with pilocytic astrocytomas. *Childs Nerv Syst* 2010;26:19–28
36. Schneider JH Jr, Raffel C, McComb JG. Benign cerebellar astrocytomas of childhood. *Neurosurgery* 1992;30:58–62; discussion 3
37. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. *Brain Pathol* 2010;20:245–54
38. Mellai M, Piazzini A, Caldera V, et al. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. *J Neuro-oncol* 2011;105:345–57
39. Pinto F, Pertega-Gomes N, Pereira MS, et al. T-box transcription factor brachyury is associated with prostate cancer progression and aggressiveness. *Clinical Cancer Res* 2014;20:4949–61
40. Toschi L, Finocchiaro G, Nguyen TT, et al. Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease. *PLoS One* 2014;9:e95303
41. Aisner DL, Nguyen TT, Paskulin DD, et al. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. *Molec Cancer Res* 2014;12:111–8
42. Schultheis AM, Bos M, Schmitz K, et al. Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer. *Mod Pathol* 2014;27:214–21
43. Yamane LS, Scapulatempo-Neto C, Alvarenga L, et al. KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy. *Oncology Rep* 2014;32:1419–26
44. Bhattacharjee MB, Armstrong DD, Vogel H, et al. Cytogenetic analysis of 120 primary pediatric brain tumors and literature review. *Cancer Gen Cytogen* 1997;97:39–53
45. Bigner SH, McLendon RE, Fuchs H, et al. Chromosomal characteristics of childhood brain tumors. *Cancer Gen Cytogen* 1997;97:125–34
46. Pfister S, Janzarik WG, Remke M, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. *J Clin Invest* 2008;118:1739–49
47. Sievert AJ, Jackson EM, Gai X, et al. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. *Brain Pathol* 2009;19:449–58
48. Bannykh SI, Mirocha J, Nuno M, et al. V600E BRAF mutation in pilocytic astrocytoma is associated with a more diffuse growth pattern but does not confer a more aggressive clinical behavior. *Clin Neuropathol* 2014;33:388–98
49. El-Osta H, Falchook G, Tsimberidou A, et al. BRAF mutations in advanced cancers: clinical characteristics and outcomes. *PLoS One* 2011;6:e25806
50. Menzies AM, Haydu LE, Visintin L, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. *Clinical Cancer Res* 2012;18:3242–9
51. Rubinstein JC, Sznol M, Pavlick AC, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. *J Transl Med* 2010;8:67
52. Sievert AJ, Lang SS, Boucher KL, et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. *Proc Natl Acad Sci USA* 2013;110:5957–62
53. Bautista F, Paci A, Minard-Colin V, et al. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. *Ped Blood Cancer* 2014;61:1101–3
54. Robinson GW, Orr BA, Gajjar A. Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. *BMC Cancer* 2014;14:258
55. Ueba T, Takahashi JA, Fukumoto M, et al. Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues. *Neurosurgery* 1994;34:221–5; discussion 5–6
56. Wynes MW, Hinz TK, Gao D, et al. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. *Clin Cancer Res* 2014;20:3299–309
57. Soria JC, DeBraud F, Bahleda R, et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. *Ann Oncol* 2014;25:2244–51
58. Nakanishi Y, Akiyama N, Tsukaguchi T, et al. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. *Molec Cancer Ther* 2014;13:2547–58